Skip to content

Effects of Video Laryngeal Mask Combined with Bronchial Blocker on Postoperative Recovery Quality in VATS Patients

Effects of Video Laryngeal Mask Combined with Bronchial Blocker on Postoperative Recovery Quality in VATS Patients

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500103026
Enrollment
Unknown
Registered
2025-05-23
Start date
2025-06-01
Completion date
Unknown
Last updated
2025-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer

Interventions

Group L:Received video laryngeal mask combined with bronchial blocker
Group D:Received double lumen tube

Sponsors

Guangzhou Institute of Cancer Research,the Afliated Cancer Hospital, Guangzhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1) Aged 18 to 65 years old; (2) Patients with solid pulmonary nodules undergoing video-assisted thoracoscopic surgery (VATS) or robotic-assisted thoracic surgery (RATS) for lung resection, including pulmonary wedge resection, segmentectomy, and lobectomy; (3) American Society of Anesthesiologists (ASA) physical status classification I–III; (4) Estimated surgical time =6 hours and postoperative hospital stay >= 2 days; (5) Voluntary participation and signed informed consent form.

Exclusion criteria

Exclusion criteria: (1) Patients with obvious airway anatomical abnormalities unsuitable for laryngeal mask and bronchial blocker use; (2) Body mass index (BMI) >= 30 kg/m^2 or =18.5 kg/m^2; (3) Allergic to any general anesthetic drugs, including propofol, sufentanil, remifentanil, etc.; (4) History of unstable angina, ischemic myocardial infarction, heart failure, or cerebrovascular accident in the past 6 months; (5) Preoperative distant tumor metastasis; (6) Preoperative severe lung diseases (pulmonary fibrosis, severe lung abscess, cor pulmonale; or FEV1 50 mmHg); (7) Poorly controlled hypertension or diabetes mellitus before surgery; (8) History of dementia, psychosis, or other neurological diseases; (9) Patients currently taking sedative medications, antidepressants, or hormones; (10) Patients with chronic pain, alcohol abuse, or drug dependence; (11) Pregnant or lactating patients; (12) Participated in other clinical trials in the past 3 months; (13) Inability to understand Mandarin or Cantonese

Design outcomes

Primary

MeasureTime frame
quality of recovery 15 at 48 hours postoperatively;

Secondary

MeasureTime frame
The incidence of sore throat within 48 hours postoperatively;HR MAP;The severity of pulmonary atelectasis at the initiation of surgery;The incidence of intraoperative hypoxemia;PPCs;Preoperative and postoperative 30-day QoR-15 scores;Time to first ambulation;Duration of drainage tube placement;Postoperative length of hospital stay;

Countries

China

Contacts

Public ContactChenlei

Guangzhou Institute of Cancer Research,the Afliated Cancer Hospital, Guangzhou Medical University

64803975@qq.com+86 20 6667 3666

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026